Company intelligence / Profile preview

Prostate Cancer Clinical Trials Consortium

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

The Prostate Cancer Clinical Trials Consortium has activated over 127 clinical trials with an active portfolio of approximately 30 ongoing studies and another ~15 pending activation. It has recruited more than 4,000 patients into Phase I and II studies. The group specializes in hypothesis-driven multicenter trials that have contributed to advancing standards of care for prostate cancer[4][6].

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Contract Research Organization

Partnerships

Prostate Cancer Foundation (PCF)U.S. Department of Defense – Prostate Cancer Research Program (DoD PCRP)

Beyond the preview

Go deeper on Prostate Cancer Clinical Trials Consortium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostate Cancer Clinical Trials Consortium.

Explore the full profile